Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: Confirmatory results from the PROCLAIM phase III clinical trial
Tithi Biswas, Rohin Gawdi, Charulata Jindal, Sharanya Iyer, Kylie H. Kang, David Bajor, Mitchell Machtay, Yuk Ming Choi, Jimmy T. Efird
Dive into the research topics of 'Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: Confirmatory results from the PROCLAIM phase III clinical trial'. Together they form a unique fingerprint.